2025 Q4 -tulosraportti
Vain PDF
124 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·52 min sittenThe Circio forum is really something else. Here are many who hold on tight and try to build each other up. If everything that has been written here in the forum were true, this share should not be at 8 kr, but 80. Deep down, most here probably know that almost all such companies are worth zero in a few years. No serious investors put their money into such cases. Only hobby investors who hope to multiply their money in the shortest possible time with sky-high risk. Good luck and thanks for the entertainment.
Alright, alright, Mr. Smarty-pants... I've clung on since the price was a little over one krone. I've recovered both what I invested and a nice little profit, which my more "serious" stocks will take many years to match. So I'm quite satisfied with being a hobby investor. If you don't have enough balls to join in, you should zip up both your pants and your mouth.
·4 t sittenWill it break today? Will it break tomorrow? Nobody knows. But I think it will break anyway. The question is not if – the question is when. Yes — if we look at the last six months, the "it's going to break"-message becomes far more substantial. I would have written it approximately like this: It's easy to sit and ask: Will it break today? Will it break tomorrow? Nobody knows. But look at what has actually happened just in the last six months. In February, in vivo data came out where circVec 4.0 showed up to 50 times higher gene expression in the eye than conventional mRNA-based AAV. At the same time, previous results of up to 40x in the heart were further validated. This is no longer just an interesting idea on the drawing board – the technology has started to produce quite extreme differences in vivo. Then the breadth starts to emerge. In March, Circio enters into a collaboration with United Immunity in in vivo cell therapy. After that comes Acuitas Therapeutics, where circVec will be evaluated in in vivo cell therapy. In April, the collaboration with Universidad de Santiago de Compostela regarding non-viral delivery of circVec comes. In May, it becomes even more interesting. Circio presents comprehensive circVec data at ASGCT 2026, with results that, according to the company, support the possibility of a significant reduction in AAV dose. The same month, they apply for an EPO patent on central parts of the circVec platform and announce a collaboration with AaviGen in heart diseases. Then comes June: collaboration with GenAssist in muscle diseases and in vivo cell therapy, then Tcelltech in CAR-T. And at the same time, the company raises 300 million kroner through warrant exercise and guaranteed emission. In July, yet another collaboration comes, this time with Avenue Biosciences, where the goal is to combine the technologies to improve protein secretion in gene therapy. And now in August, Circio has also been selected for an oral presentation at ESGCT's annual meeting. That is why I believe one must see the forest and not just each individual tree. In half a year, we have thus seen 50x data in the eye, further validation in the heart, ASGCT data, new patent moves, several research collaborations across AAV, non-viral delivery, muscle disease, CAR-T and in vivo cell therapy – while the company has raised significant capital. Is this a guarantee for an acquisition or a license agreement? Of course not. It would be unserious to claim. But the direction is hard to overlook. Six months ago, one could to a much greater extent discuss whether circVec was primarily an exciting technology. Now the question is becoming how broadly the technology can actually work, who will validate it, and how strong the data will be when these collaborations start delivering results. So, will it break today? Will it break tomorrow? No idea. But if Circio continues to deliver data and external validations at the same pace as in the last six months, I believe the probability of something bigger happening just gets higher and higher. That's why I say: For me, it's no longer just about whether it breaks. The interesting thing is what triggers it – and how big the break will be.
·5 t sittenWiklund has consistently been very positive about the milestone picture for the next 6–12 months, and Gaal has previously described the potential in circRNA as very large. But that, of course, does not mean that management can guarantee positive results. What is documentable is that Circio is now entering a period with several parallel R&D and partner tracks, full funding for several years, and a circVec platform that the company itself describes as globally leading in vector-based circRNA. That is more than enough for the coming months to be exceptionally interesting – without putting stronger words in the mouth of management than they have actually used.
But has anyone done that? Wiklund probably said in a Web, k, that this had the potential for 10 times at a higher price than what we are at today.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
124 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·52 min sittenThe Circio forum is really something else. Here are many who hold on tight and try to build each other up. If everything that has been written here in the forum were true, this share should not be at 8 kr, but 80. Deep down, most here probably know that almost all such companies are worth zero in a few years. No serious investors put their money into such cases. Only hobby investors who hope to multiply their money in the shortest possible time with sky-high risk. Good luck and thanks for the entertainment.Alright, alright, Mr. Smarty-pants... I've clung on since the price was a little over one krone. I've recovered both what I invested and a nice little profit, which my more "serious" stocks will take many years to match. So I'm quite satisfied with being a hobby investor. If you don't have enough balls to join in, you should zip up both your pants and your mouth.
- ·4 t sittenWill it break today? Will it break tomorrow? Nobody knows. But I think it will break anyway. The question is not if – the question is when. Yes — if we look at the last six months, the "it's going to break"-message becomes far more substantial. I would have written it approximately like this: It's easy to sit and ask: Will it break today? Will it break tomorrow? Nobody knows. But look at what has actually happened just in the last six months. In February, in vivo data came out where circVec 4.0 showed up to 50 times higher gene expression in the eye than conventional mRNA-based AAV. At the same time, previous results of up to 40x in the heart were further validated. This is no longer just an interesting idea on the drawing board – the technology has started to produce quite extreme differences in vivo. Then the breadth starts to emerge. In March, Circio enters into a collaboration with United Immunity in in vivo cell therapy. After that comes Acuitas Therapeutics, where circVec will be evaluated in in vivo cell therapy. In April, the collaboration with Universidad de Santiago de Compostela regarding non-viral delivery of circVec comes. In May, it becomes even more interesting. Circio presents comprehensive circVec data at ASGCT 2026, with results that, according to the company, support the possibility of a significant reduction in AAV dose. The same month, they apply for an EPO patent on central parts of the circVec platform and announce a collaboration with AaviGen in heart diseases. Then comes June: collaboration with GenAssist in muscle diseases and in vivo cell therapy, then Tcelltech in CAR-T. And at the same time, the company raises 300 million kroner through warrant exercise and guaranteed emission. In July, yet another collaboration comes, this time with Avenue Biosciences, where the goal is to combine the technologies to improve protein secretion in gene therapy. And now in August, Circio has also been selected for an oral presentation at ESGCT's annual meeting. That is why I believe one must see the forest and not just each individual tree. In half a year, we have thus seen 50x data in the eye, further validation in the heart, ASGCT data, new patent moves, several research collaborations across AAV, non-viral delivery, muscle disease, CAR-T and in vivo cell therapy – while the company has raised significant capital. Is this a guarantee for an acquisition or a license agreement? Of course not. It would be unserious to claim. But the direction is hard to overlook. Six months ago, one could to a much greater extent discuss whether circVec was primarily an exciting technology. Now the question is becoming how broadly the technology can actually work, who will validate it, and how strong the data will be when these collaborations start delivering results. So, will it break today? Will it break tomorrow? No idea. But if Circio continues to deliver data and external validations at the same pace as in the last six months, I believe the probability of something bigger happening just gets higher and higher. That's why I say: For me, it's no longer just about whether it breaks. The interesting thing is what triggers it – and how big the break will be.
- ·5 t sittenWiklund has consistently been very positive about the milestone picture for the next 6–12 months, and Gaal has previously described the potential in circRNA as very large. But that, of course, does not mean that management can guarantee positive results. What is documentable is that Circio is now entering a period with several parallel R&D and partner tracks, full funding for several years, and a circVec platform that the company itself describes as globally leading in vector-based circRNA. That is more than enough for the coming months to be exceptionally interesting – without putting stronger words in the mouth of management than they have actually used.But has anyone done that? Wiklund probably said in a Web, k, that this had the potential for 10 times at a higher price than what we are at today.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
124 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·52 min sittenThe Circio forum is really something else. Here are many who hold on tight and try to build each other up. If everything that has been written here in the forum were true, this share should not be at 8 kr, but 80. Deep down, most here probably know that almost all such companies are worth zero in a few years. No serious investors put their money into such cases. Only hobby investors who hope to multiply their money in the shortest possible time with sky-high risk. Good luck and thanks for the entertainment.Alright, alright, Mr. Smarty-pants... I've clung on since the price was a little over one krone. I've recovered both what I invested and a nice little profit, which my more "serious" stocks will take many years to match. So I'm quite satisfied with being a hobby investor. If you don't have enough balls to join in, you should zip up both your pants and your mouth.
- ·4 t sittenWill it break today? Will it break tomorrow? Nobody knows. But I think it will break anyway. The question is not if – the question is when. Yes — if we look at the last six months, the "it's going to break"-message becomes far more substantial. I would have written it approximately like this: It's easy to sit and ask: Will it break today? Will it break tomorrow? Nobody knows. But look at what has actually happened just in the last six months. In February, in vivo data came out where circVec 4.0 showed up to 50 times higher gene expression in the eye than conventional mRNA-based AAV. At the same time, previous results of up to 40x in the heart were further validated. This is no longer just an interesting idea on the drawing board – the technology has started to produce quite extreme differences in vivo. Then the breadth starts to emerge. In March, Circio enters into a collaboration with United Immunity in in vivo cell therapy. After that comes Acuitas Therapeutics, where circVec will be evaluated in in vivo cell therapy. In April, the collaboration with Universidad de Santiago de Compostela regarding non-viral delivery of circVec comes. In May, it becomes even more interesting. Circio presents comprehensive circVec data at ASGCT 2026, with results that, according to the company, support the possibility of a significant reduction in AAV dose. The same month, they apply for an EPO patent on central parts of the circVec platform and announce a collaboration with AaviGen in heart diseases. Then comes June: collaboration with GenAssist in muscle diseases and in vivo cell therapy, then Tcelltech in CAR-T. And at the same time, the company raises 300 million kroner through warrant exercise and guaranteed emission. In July, yet another collaboration comes, this time with Avenue Biosciences, where the goal is to combine the technologies to improve protein secretion in gene therapy. And now in August, Circio has also been selected for an oral presentation at ESGCT's annual meeting. That is why I believe one must see the forest and not just each individual tree. In half a year, we have thus seen 50x data in the eye, further validation in the heart, ASGCT data, new patent moves, several research collaborations across AAV, non-viral delivery, muscle disease, CAR-T and in vivo cell therapy – while the company has raised significant capital. Is this a guarantee for an acquisition or a license agreement? Of course not. It would be unserious to claim. But the direction is hard to overlook. Six months ago, one could to a much greater extent discuss whether circVec was primarily an exciting technology. Now the question is becoming how broadly the technology can actually work, who will validate it, and how strong the data will be when these collaborations start delivering results. So, will it break today? Will it break tomorrow? No idea. But if Circio continues to deliver data and external validations at the same pace as in the last six months, I believe the probability of something bigger happening just gets higher and higher. That's why I say: For me, it's no longer just about whether it breaks. The interesting thing is what triggers it – and how big the break will be.
- ·5 t sittenWiklund has consistently been very positive about the milestone picture for the next 6–12 months, and Gaal has previously described the potential in circRNA as very large. But that, of course, does not mean that management can guarantee positive results. What is documentable is that Circio is now entering a period with several parallel R&D and partner tracks, full funding for several years, and a circVec platform that the company itself describes as globally leading in vector-based circRNA. That is more than enough for the coming months to be exceptionally interesting – without putting stronger words in the mouth of management than they have actually used.But has anyone done that? Wiklund probably said in a Web, k, that this had the potential for 10 times at a higher price than what we are at today.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt